Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 79Nasopharyngeal Carcinoma 51Uterine Cervical Neoplasms 44Lung Neoplasms 38Esophageal Neoplasms 32Head and Neck Neoplasms 28Esophageal Squamous Cell Carcinoma 28Squamous Cell Carcinoma of Head and Neck 22Stomach Neoplasms 20Breast Neoplasms 16Small Cell Lung Carcinoma 15Recurrence 12Neoplasm Metastasis 12Nasopharyngeal Neoplasms 12Carcinoma, Squamous Cell 10Ovarian Neoplasms 9Central Nervous System Neoplasms 9Neuroblastoma 8Lymphoma, Large B-Cell, Diffuse 8Pancreatic Neoplasms 7Lymphoma 7Hypopharyngeal Neoplasms 7Triple Negative Breast Neoplasms 6Oropharyngeal Neoplasms 6Neoplasms 6Biliary Tract Neoplasms 6Urinary Bladder Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Follicular 5

Interventions

eribulin 2tislelizumab 1camrelizumab 1anlotinib 1Vinorelbine 1Taxes 1Epirubicin 1Doxorubicin 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × HER2-negative Breast Cancer × Cisplatin × Clear all
NCT04848454 2022-10-18

Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

Peking University First Hospital

Phase 2 Unknown
30 enrolled
Breast

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡